Medscape7h
Chronic Skin Effects Persist After Cancer Immunotherapy
Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...
GlobalData on MSN10h
OSE announces overall survival success in Phase II PDAC vaccine trial
The Phase II trial examined the therapeutic cancer vaccine Tedopi in combination with chemotherapy drug combination FOLFIRI.
Pharmaceutical Technology6h
Ono earmarks $940m to gain rare blood cancer therapy from Ionis
Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia ...
Labiotech.eu8h
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Updated clinical & translational results: BOND-003 Cohort C- A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder ...
Targeted Oncology10h
High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy
An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) ...
Pharmac Funding Decision Will Increase Medicines Access
Pharmac has today announced their decision to fund six medicines for cancer, including a combination treatment, and one ...
Mirage News20h
Pharmac Funding Boost Expands Medicines Access 12 March
Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac's decision to fund medicines ...